







T2T Site Newsletter



Seasonal Wishes from the T2T in Gout Trial Thank you for your continued support

A message from the Chief Investigator, Prof. Abhishek.

Thank you very much for supporting the T2T trial. I hope you could find time to take a break in the summer. While recruitment is completed, participants continue to be followed up in the trial. Thank you very much for supporting this important phase of the trial. I look forward to sharing the results with you in late 2026.

Just a reminder...

It is important that patients continue to be followed up, even if they have moved to a different GP practice. If you are unsure of the procedure, please contact the Trial Manager for guidance.

We are currently reviewing delegation logs to ensure we have the most up-to-date version for each site. If there have been any staff changes (or other updates) at your site, please send us an updated delegation log by email.

Recent updates:

Recent Amendments: NSA19, to extend the study until August 2028 to cover 4 year follow up at all sites and NSA20, to clarify RDN staff can collect data at site for the 4 year follow up Medical Record Review have been approved since the last update.

MDC process reminder: The MDC process is now in place for 2-year follow-up. Please use this if you are unable to get in contact with a participant.

Medical Record Review: Completion of CRF10 will be requested at the 4-year post-randomisation point and will be provided via an online link. Once all CRF10 forms have been received for all participants at your site, the site closure procedure will begin.

Site closure preparation: When preparing to close your site, please ensure your Investigator Site File (ISF) is up to date. If you require a copy of the list of current document versions that should be included in your ISF, please get in touch with the Trial Manager.

Contact the T2T trial manager | 01782 732950 | steff.garvin@nhs.net

